-
GenSight Biologics Secures Funding to Advance AAV-Based Gene Therapies for Blinding Eye Diseases
Jul 17 2025 -
Rocket Pharma’s RP-A601 AAV Gene Therapy for PKP2-ACM Earns FDA RMAT Designation
Jul 17 2025 -
Genascence’s AAV Gene Therapy for Knee OA Earns FDA RMAT Designation
Jul 16 2025 -
AAVantgarde Bio Gains FDA IND Clearance for Dual AAV Gene Therapy AAVB-039 for Stargardt Disease
Jul 16 2025 -
New CMS Model Aims to Unlock Access to Sickle Cell Gene Therapies
Jul 16 2025 -
Sarepta Undergoes Major Restructuring, Prioritizes siRNA After Gene Therapy Pipeline Pivot
Jul 16 2025 -
Sanofi’s SAR446597 Gene Therapy for Geographic Atrophy Granted FDA Fast Track Designation
Jul 16 2025 -
Medera Doses First Patient in AAV Gene Therapy Trial for DMD Cardiomyopathy
Jul 15 2025 -
Imugene’s Off-the-Shelf CAR T-Cell Therapy Shows Potent Responses in DLBCL Trial
Jul 14 2025